Novavax said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a stand-alone flu vaccine, sending shares of the company down sharply.

The vaccine maker said the regulator placed the hold because of a report of a “serious adverse event” of motor neuropathy in one clinical-trial participant outside the U.S.

The U.S. Food and Drug Administration has put Novavax's trial of an experimental COVID-flu vaccine combination on hold after one person who received the shot reported nerve damage, the company said on Wednesday.

Novavax Inc.’s stock tumbled 19% early Wednesday after the company said the Food and Drug Administration has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates,

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined Covid-flu vaccine and standalone flu inoculation due to safety concerns. Fi

The Food and Drug Administration halted Novavax's trial of a combination vaccine for COVID and influenza, as well as a standalone flu shot, after a participant suffered a serious adverse event, the company said on Wednesday.

Novavax's shares are tumbling after the company disclosed that regulators paused clinical trials for two key vaccine candidates.